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g.2012.0Abstract A disintegrin and metalloproteinase-encoding gene (ADAM33), was recently identiﬁed
as an asthma susceptibility gene. ADAM33 protein is expressed in smooth muscle cells of bronchi
and pulmonary ﬁbroblasts, playing a major role in airway remodeling. Earlier studies, have mostly
conﬁrmed a link between ADAM33 and asthma as well as bronchial hyperresponsiveness. This
work studied a group of Egyptian asthmatic children for 3 ADAM33 single nucleotide polymor-
phisms (SNPs), previously identiﬁed as putative risk alleles: T1 G > A(rs2280091), T2
A >G(rs2280090), V4 G > C(rs2787094) using Polymerase Chain Reaction – restriction fragment
length polymorphism (PCRRFLP) with emphasis on their relation to clinical (severity, smoking,
family history, and atopic manifestations) and laboratory data (Ig Immunoglobulin E (Ig E) level
and absolute eosinophilia) and pulmonary functions. Sixty (3–12 years old) asthmatic children and
32 matched controls were recruited. The genotype distribution for the SNPs showed no signiﬁcant
difference between the patients and the controls. A higher frequency of the (AA) genotype of T1
polymorphism was found in controls (75%) than in patients (41%), while the (AG) variant was
higher in cases (46.6%) than in controls (21.9%) but with no statistically signiﬁcant difference. Also
the (GG) genotype was higher in cases (11.6%) than in controls (3.1%) but with no statistical sig-
niﬁcance. The allelic frequencies of T1 showed a higher (A) allele in controls (85.93%) than casesEl-Sheikh Al-Khodary St.,
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56 M.M. El-Falaki et al.(65%) and higher (G) allele in cases (35%) than controls (14.06%), showing a high signiﬁcant
difference. No correlation was found between (T1, T2, and V4) and the demographic, clinical
and laboratory parameters, except SNP T1 showing a positive correlation with Ig E level, and
SNP V4 showing a positive correlation with passive smoking as a precipitating factor and border-
line signiﬁcance with absolute eosinophilia. In conclusion, no signiﬁcant association was detected
between these SNPs and asthma susceptibility in this study.
 2012 Ain Shams University. Production and hosting by Elsevier B.V. All rights reserved.1. Introduction
Asthma can be considered as a multifactorial disease showing
heterogeneous phenotypes. It manifests as episodes of wheez-
ing, coughing, and shortness of breath particularly at night.
Both family-based and twin studies indicate that asthma is a
complex genetic disorder. Multiple genetic and environmental
factors are known to modulate the clinical expression of the
disease and its associated phenotypes: bronchial hyper respon-
siveness, atopy and elevated Ig E [1].
Bronchial asthma is prevalent worldwide, especially in
developed countries where its prevalence is increasing to epi-
demic proportions [2]. Asthma comprises a range of heteroge-
neous phenotypes that differ in presentation, etiology and
pathophysiology. The risk factors for each recognized pheno-
type of asthma include genetic, environmental and host fac-
tors. The common positive family history in asthma does not
necessitate or sufﬁce for the development of the disease [3].
ADAM33, an asthma candidate gene identiﬁed through a
genome-wide scan for asthma susceptibility genes, may be
associated with childhood asthma, lung function decline and
bronchial hyperresponsiveness [4]. The ADAM33 gene is lo-
cated on chromosome 20p13 and 37 single nucleotide polymor-
phisms (SNPs) have initially been identiﬁed. Recently, several
SNPs in the ADAM33 gene have been shown to be signiﬁ-
cantly associated with asthma, BHR, and atopy [5]. Studies
on the expression of ADAM33 mRNA in human cells and tis-
sues have revealed exclusive distribution of this protein in cells
of mesenchymal origin such as ﬁbroblasts and smooth muscle
cells, which indicate a possible role for ADAM33 in airway
remodeling deﬁned as changes in airway structure that increase
the predisposition to allergic sensitization [6].
The aim of this study was to validate the association of
ADAM33 polymorphisms to asthma in a separate well charac-
terized population through a case-control study and to assess
its correlation to clinical (age, sex, duration, severity, etc.), lab-
oratory (total serum Ig E, absolute eosinophilic count) and
pulmonary function parameters.
2. Subjects and methods
This study is a cross sectional case-controlled observational
study. Sixty asthmatic children were recruited from the pediat-
ric allergy clinic of Cairo University Specialized Pediatric Hos-
pital. The inclusion criteria for patients included age groups
between 3 and 12 years with asthma diagnosis according to
the global initiative for asthma guidelines (GINA 2009) [7]
and not receiving long term anti-asthma controller medica-
tions. Exclusion criteria included patients having history of
birth prematurity, requirement of incubator care, ventilation
and/or intubation in the neonatal period or beyond or patientshaving a suspected or previous alternative cause for recurrent
wheezing. This study also excluded those patients receiving
long term anti-asthma medications or those on systemic
steroids at the time of sampling or within the previous 2 weeks.
An informed written consent was signed by parents of all
children included in the study.
2.1. Methods
All patients and controls were subjected to the following:
2.1.1. Clinical assessment
 Full history taking according to the standard sheet of
allergy clinic, New Children’s Hospital, Cairo University
with emphasis on:
– Personal data: age, sex, family history of smoking,
animal contact.
– Location: Urban, rural, semi urban.
– History of present illness such as duration of the dis-
ease, upper respiratory symptoms, chest symptoms,
atopic manifestations, seasonal variations, pattern
of symptoms, severity and precipitating factors.
– Past history of allergies, infections, etc.
– Family history of asthma or other allergic conditions.
– Perinatal history.
 Thorough clinical examination with special reference to:
– General examination especially respiratory distress,
cyanosis, etc.
– Limb and skin examination for atopic manifestations.
– Chest examination.
N.B. The sheet kept a record of investigations done for the
patients, the medication used by the patient during the attack
and prophylaxis and any other drug if stated.
2.1.2. Laboratory investigations
2.1.2.1. Total blood cell count. Ethylene diamine trisodium ace-
tate (EDTA) collected venous blood was assayed on a Colter
(STKS) automated cell counter. Absolute eosinophil count
above 400 cells/cm3 was considered absolute eosinophilia.
2.1.2.2. Quantization of total serum Ig E. Venous blood col-
lected in serum separator tubes (SSTs) was allowed to clot.
After centrifugation serum was separated and stored at
20 C until assayed.
Total serum Ig E was assayed using commercially available
monoclonal antibody based enzyme immunoassay by (Diamed
Eurogen, Turnhout Belgium). In brief microtitre strips pre-
coated with anti-Ig E monoclonal antibody were incubated
with patients’ sera and a second anti-Ig E antibody conjugated
Table 1 Primers and PCR programs for ADAM33 PCR-RFLP genotyping.
Reference SNP ID Gene/SNP primer Sequence PCR Program
rs2280091 ADAM33 T1G/A F 50 ACTCAAGGTGACTGGGTGCT 30 94 C 5 min; 35 cycles, 94 C 30 s, 54 C 30 s,
72 C 30 s; 72 C 5 min
ADAM33 T1G/A R 50 GAGGGCATGAGGCTCACTTG 30
rs2280090 ADAM33 T2A/G F 50 TTCTCAGGGTCTGGGAGAAA 30 94 C 5 min; 35 cycles, 94 C 30 s, 52 C 30 s,
72 C 30 s; 72 C 5 min
ADAM33 T2A/G R 50 GCCAACCTCCTGGACTCTTA 30
rs2787094 ADAM33 V4C/G F 50 ACACACAGAATGGGGGAGAG 30 94 C 5 min; 35 cycles, 94 C 30 s, 53 C 30 s,
72 C 30 s; 72 C 5 min
ADAM33 V4C/G R 50 CCAGAAGCAAAGGTCACACA 30
Table 3 Patient distribution as regards age.
Patient no. 60 Patients
Age Range 3–12 yrs
Age mean and SD 6.45 ± 2.64
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were determined by incubating with substrate solution and a
color developed in proportion to the amount of immune com-
plexes bound to the wells. After stopping the reaction the ODs
(optical densities) were read at 450 nm.
2.1.2.3. Genotyping. In this study we studied 3 ADAM33 gene
SNPs (single nucleotide polymorphisms), which have previ-
ously been shown to have an allelic and/or haplotype associa-
tion with asthma, including T1(rs2280091) G/A,
T2(rs2280090) A/G and V4(rs2787094) C/G by PCR-RLFP
(restriction fragment length polymorphism) [8,9]. The poly-
morphic region was ampliﬁed by PCR using a 9600 PE Ther-
mal Cycler (Perkin Elmer, USA). The PCR reaction for each
SNP was carried out by adding genomic DNA (10 pg-1ug)
to Dream TaqT PCR master mix 12.5 ll (Fermentas, Ger-
many) [0.05 U Taq DNA polymerase, reaction buffer, 4 mM
MgCl2, and 0.4 mM of each dNTP],and 1 ll of each primer
(10 pmol) in a total volume of 25 ll. Primer sequence and
PCR conditions are listed in [Table 1].
The ampliﬁed DNA was then digested by the restriction en-
zymes NcoI, HpyCH4III, and PstI for T1, T2 and V4 respec-
tively (Ferments, Germany) (Table 2) and the fragments were
visualized on ethidium bromide stained 2% agarose gel which
were run alongside a 50 bp ladder molecular weight marker
(GelPilot 50 bp Ladder (100) from Qiagen).
2.1.3. Pulmonary function tests
Spirometric measurements including forced vital capacity
(FVC), forced expiratory volume in 1 s (FEV1) and forced
expiratory ﬂow between 25% and 75% expired volume
(FEF25-75) were done using a Jaeger MasterScreen Spirometry
System (Jaeger Co, Wurzburg, Germany). Percent predictedTable 2 Restriction enzyme digestion of PCR products for
T1, T2 and V4.
SNP Restriction enzyme Digested fragment sizes
T1 NcoIa G allele: 140 bp and 260 bp
A allele: 400 bp
T2 HpyCH4III* A allele: 198 bp and 112 bp
G allele: 310 bp
V4 PstI* C allele: 374 bp
G allele: 168 and 206
a Fermentas, Germany.values for spirometry measurements were based on age, height,
sex, and ethnicity.
A Jaeger Master Screen Impulse Oscillometry System (Jae-
ger Co, Wurzburg, Germany) was also used to assess pulmon-
ary functions in both patients and controls.
2.2. Statistical analysis
Data are presented as the range, the mean ± standard devia-
tion or as a number (percentages). Comparison between
groups was analyzed by Student’s t-test and categorical vari-
ables were compared using the Pearson Chi-Square test or
Fisher’s exact test. Correlations were assessed using Spear-
man’s correlation coefﬁcients for categorical values. Statistical
analysis of data was done using Microsoft Excel 2007 (Micro-
soft Corporation, NY, USA) and SPSS (Statistical Package for
Social Sciences; SPSS Inc., Chicago, Il, USA) version 15 for
Microsoft Windows. A probability value (p-value) less than
0.05 was considered statistically signiﬁcant.
3. Results
3.1. Basic demographic and clinical data
Demographic and clinical data of patients in the present study
are shown in (Tables 3 and 4).
3.2. Comparative data
Although both total Ig E level and absolute eosinophil count
were signiﬁcantly higher in patients than controls (Table 5),
however no statistical correlation between total Ig E and the
absolute eosinophil count in cases was found (Fig. 1).
Neither the Ig E level nor the absolute eosinophil count
showed any statistically signiﬁcant correlation with the level
of asthma severity in patients, the presence of other atopic
manifestations or the presence of positive family history. How-
ever a statistical signiﬁcant correlation between the pulmonary
Table 4 Other demographic and clinical data distribution
among patient group.
Variables Patient No. Percentage
Gender
Males 35 58.3
Females 25 41.7
Residence
Urban 29 46.7
Semi Urban 21 33.3
Rural 10 15
Disease severitya
Intermittent 18 30
Mild persistent 26 43.3
Moderate persistent 16 26.9
Family history of allergic diseasesb
Negative 20 33.3
Positive 40 66.7
Other atopic conditionsc
Negative 48 80
Positive 12 20
a Classiﬁcation of asthma severity is based on The Global Ini-
tiative for Asthma (gina) guidelines [7].
b Family history of allergic diseases: conjunctivitis, allergic rhi-
nitis, skin allergy and bronchial asthma.
c Other atopic conditions: Conjunctivitis, allergic rhinitis,
eczema, urticaria and drug eruptions.
Figure 1 Scatter diagram showing the correlation between Ig E
and absolute eosinophilic count in the cases.
58 M.M. El-Falaki et al.function results and the absolute eosinophil count but not the
Ig E level was identiﬁed (Table 8).
Although, there was no statistical signiﬁcant difference in
the expression of the different genotypes of either of the 3
ADAM33 SNPs between cases and controls, the analysis of
the allelic frequencies for each polymorphism showed a signif-
icantly higher tendency of the G allele in cases and the A allele
in controls for the ADAM33 T1 polymorphism alone (Tables
6 and 7). The PCR-RFLP results are demonstrated in (Figs. 2
and 3).
No correlation was found between ADAM33 T1 polymor-
phism and the different laboratory and clinical data in the pa-
tients of our study, with the exception of the total Ig E level
which was statistically signiﬁcantly higher in the GG genotype
patient group (Table 9).
No correlation was observed between the ADAM33 T2
polymorphism and any of the laboratory or clinical data in
the patients of the study.
A comparison between the ADAM33 V4 genotypes and the
different laboratory and clinical data in the patient groupTable 5 Comparison between mean values of IgE level and total e
Variables Patients (n= 60)
Range M
Ig E level (IU/ml) 5–500 11
Absolute Eosinophilic Count (cells/cmm) 11–1620 52
* p-Value is signiﬁcant if 60.05.showed a signiﬁcant correlation between CG genotype and
passive smoking as a precipitating factor (Table 10) but with
none of the other parameters studied.
4. Theory
Pathogenesis of complex polygenic disorders is dependent on a
3-dimensional multiplex interaction. The gene, the environ-
ment and time are 3 independent factors that must be consid-
ered when conducting studies that should be run in a
bidirectional mode. The three variables, themselves, pose a
great difﬁculty when conducting studies to elucidate any given
effect. A classic model for polygenic disorders, is allergic dis-
eases whose relevant genes might vary depending not only
on the environmental exposures but also, on the age and devel-
opmental stage at exposure. This ﬁnal dimension of time fur-
ther complicates the situation, in as much as certain genetic
and environmental inﬂuences might be relevant only during
a speciﬁc developmental stage ‘‘windows of opportunity’’.
Furthermore, multiple genetic and environmental inﬂuences
occur simultaneously, and the collective contributions might
be quite different from what is anticipated from any isolated
individual effect as a result of the co-existing genetic and envi-
ronmental subtext. Dissecting the effect of the environmental
context might foster preventive and therapeutic strategies pre-
dicted on innocuous surrogates or antagonists of the exposures
found to be associated with the phenotypes of interest in
susceptible individuals. Genetic dysregulation in allergy and
asthma hits multiple steps in key pathways, with small effects.
The smaller the effects, the larger a study population needs to
be for those effects to become appreciable, but the larger the
population, the more difﬁcult it is to control for environmental
factors, hence, targeted recruitment efforts collecting a wealth
of relevant environmental data might provide exciting break-
through, even when more limited in size [10].osinophilic count in the patient and control groups.
Controls (n= 32) p-Value
ean ± SD Range Mean ± SD
6 ± 129 6–250 49.2 ± 58 0.001*
3 ± 511 7–41 19.5 ± 9.4 0.0001*
Table 6 Results of the PCR–RFLP for ADAM33 T1, T2 and V4 genotypes in patients and controls.
SNP Genotype Cases N= 60 Controls N= 32 p-Value Odds Ratio 95% conﬁdence interval
Lower Upper
ADAM33 T1 Homozygous (GG genotype) 25(41.7%) 24(75%)
Heterozygous (AG genotype) 28(46.7%) 7(21.9%) 0.085 6.72 0.77 58.79
Wild type (AA genotype) 7(11.6%) 1(3.1%) 0.625 1.75 0.18 16.65
ADAM33 T2 Homozygous (AA genotype) 6(10%) 0(0%)
Heterozygous (AG genotype) 21(35%) 18(56.3%) 0.999 0.00 0.00 0.00
Wild type (GG genotype) 33(55%) 14(43.8%) 0.12 2.02 0.83 4.91
ADAM33 V4 Homozygous (CC genotype) 8(13.3%) 6(18.8%)
Heterozygous (CG genotype) 48(80%) 25(78.1%) 0.7 6.375 4.68 0.46
Homozygous (CC genotype) 4(6.7%) 1(3.1%) 0.78 4.33 5.1 1.2
Table 7 Analysis of allelic frequencies for T1, T2 and V4
polymorphisms in patients and controls.
SNP Allele Cases Controls p-Value
ADAM33 T1 A allele 78(65%) 55(85.93%) 0.003*
G allele 42(35%) 9(14.06%)
ADAM33 T2 A allele 33(27.5%) 18(28.12%) 0.885
G allele 87(72.5%) 46(71.87%)
ADAM33 V4 C allele 64(53.3%) 37(57.8%) 0.567
G allele 56(46.6%) 27(42.2%)
* p-Value is signiﬁcant if 6 0.05.
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The genotype distributions were not statistically different be-
tween patients and controls in any of the 3 SNPs under study.
Although there was a difference in the frequency of expression
of T1 (AA) genotype between cases (41.7%) and controls
(75%) and T1 (AG) genotype which was nearly 2 folds in cases
(46.7%) in comparison to controls (21.9%), and similarly anFigure 2 2% agarose gel for PCR-RFLP of ADAM33 T2
polymorphism digested by HpyCH4III. Lane 16: 50 bp ladder
molecular weight marker. Lanes 1, 2 and 4: A single 310 bp band
representing homozygous GG allele. Lanes 3, 5, 6 and 9: 198 and
112 bp bands representing homozygous AA allele. Lanes 8, 10, 11,
12, 13 and 15: 310, 198 and 112 bp bands representing heterozy-
gous AG allele. Lane 7: Inconclusive (was repeated).increased expression of T2 (GG) genotype in patient group
and (AG) genotype in the controls was observed, but due to
the number of cases no statistical signiﬁcance could be
detected. This higher incidence of G allele in the cases and A
allele in the controls is suggestive that A allele may have a
protective role against asthma and that G allele may be a sus-
ceptibility gene for asthma.
These ﬁndings are in agreement with a study done to eluci-
date the role of ADAM33 polymorphisms in a genetic analysis
of a German case control study on 1872 children and longitu-
dinal cohort study (824 children) that showed none of ten
ADAM33 SNPs to have signiﬁcant association with doctor’s
diagnosis [5]. Similar results were observed in a study carried
out in a Colombian population, that genotyped 6 ADAM 33
SNPs including T1, T2 and V4 in 429 asthmatics, 401 controls
and 116 family trios. However they reported a positive statis-
tical signiﬁcant association between the H4 haplotype
(GCAGGG) and asthma [11]. A third study, published in
2012, carried out on a small cohort of 89 cases in the Japanese
population did not report an association between the SNPs in-
cluded in our study and asthma, but its results suggested thatFigure 3 2% agarose gel for PCR-RFLP of ADAM33 V4
polymorphism digested by PstI. Lane 1: 50 bp ladder molecular
weight marker. Lanes 2 and 6: single band at 374 bp representing
homozygous CC allele. Lanes 3, 4, 5, 7, 8, 9, 10, 11, 12: 374 bp
band (C allele) and 168 and 206 bp bands (G allele) representing
heterozygous CG genotype.
Table 8 Comparison between pulmonary function results and the total Ig E levels and the absolute eosinophilic count in the patient
group.
Pulmonary functions p-Value
Normal Abnormal
N Median(range) N Median(range)
Absolute eosinophilic Count 36 420.00(15–1620) 24 240.00(11–1300) 0.025*
Ig E 36 77.500(5–500) 24 68.750(5–500) 0.700
* p-Value is signiﬁcant if 6 0.05.
Table 9 Comparison between T1 genotypes and absolute eosinophilic count and Ig E level.
Polymorphism ADAM33T1 p-Value
Genotype AA AG GG
Statistical test N Median(range) N Median(range) N Median(range)
Absolute eosinophilic count 25 240.00(11–1610) 28 400.00(15–1620) 7 490.00(55–1550) 0.479
Ig E 25 80.0(5–500) 28 58.750(5–315) 7 178.0(48.5–400) 0.047*
* p-Value is signiﬁcant if 6 0.05.
Table 10 Comparison between V4 genotypes and smoking as
a precipitating factor.
Genotype (V4) Passive smoking
Positive
(N= 35%)
Negative
(N= 25%)
p-Value
CC genotype 0(0%) 8(32.0%) 0.001*
CG genotype 33(94.3%) 15(60.0%)
GG genotype 2(5.7%) 2(8.0%)
* p-Value is signiﬁcant if 6 0.05.
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associated with the disease [12]. A similar conclusion was pro-
posed by a study in an Eastern Chinese population [13]. Other
studies on variable populations (Icelandic, UK, non-Hispanic
white and African American, German and Korean) gave con-
cordant results [5,14–16].
However contrasting results emerged from studies done on
similar and other ethnicities, where signiﬁcant association was
noted between ADAM33 T1, T2 and V4 and asthma
(p< 0.0001) in Chinese Han population [9] and also between
ADAM 33 V4 and asthma in the US population (p= 0.032)
[16] and between T2 and childhood asthma in Japanese popu-
lation [8].
In either case replication studies in larger and different
asthma populations are required to identify the genetic rela-
tionship between ADAM33 and disease [17].
In the current study, investigating the association between
ADAM33 polymorphism and pulmonary functions
(IOS ± spirometry) according to age in asthmatic patients
was of prime concern. No signiﬁcant statistical association be-
tween SNP T1, T2 and V4 and the affection of pulmonary
functions (p-value = 0.872, 0.93, and 0.643 respectively) was
proved. Contrarily a number of studies reported an accelerated
decline in lung functions in asthmatic patients particulary with
T1 and T2 genotypes [9,18–22]. Given the contributory role ofADAM33 in bronchial remodeling, it would be worth analyz-
ing its association with traits other than pulmonary functions;
still the insigniﬁcant results may be attributed to the small size
in this study.
In the present study, comparing different genotypes of
ADAM33 T1, T2, and V4 genotypes among asthmatic patients
with the level of asthma severity, revealed no statistical signif-
icance (p-value = 0.538, 0.237, and 0.471 respectively). This
was in accordance with other studies, where no association be-
tween asthma severity and any of 10 SNPs (including V4 only)
was found in an Australian population [23] while no evidence
for the same association was proved between either T1, T2, or
V4 and asthma severity, bronchodilator response or Ig E levels
in Mexican Americans, Puerto Ricans or the combined popu-
lation [24]. However a recent Egyptian study reported that the
beta-2 adrenoreceptor (b2AR) gene polymorphism Arg16Gly
appears to be an important genetic factor in the expression
of asthma severity [25].
In this study, comparing the genetic polymorphism of
ADAM33 among atopic asthmatic patients (allergic rhinitis
and dermatitis) versus non-atopic asthmatics, showed no sta-
tistical signiﬁcant difference between both groups in any of
the SNPs T1, T2 and V4 (p-value = 0.698, 0.181, and 0.43).
Similarly a study done on the Japanese population showed
no association between the risk of atopic dermatitis and either
T1, T2 or V4 polymorphisms but a positive correlation with
other ADAM33 polymorphisms [26].
The present study found no signiﬁcant statistical association
between positive family history in the asthmatic patient and
either T1, T2, or V4 polymorphisms (p-value: 0.543, 0.851,
and 0.68). This was in partial agreement with a study done
on an Indian population where no association between positive
family history and the V4 polymorphism was observed [27].
A statistical signiﬁcant relation was observed between
ADAM33 T1 polymorphism and total Ig E level, but none with
T2 and V4. Also no signiﬁcant relation could be detected be-
tween ADAM33 T1, T2 and V4 polymorphisms and the abso-
lute eosinophilic count. The study performed on a Colombian
A disintegrin and metalloproteinase 33 (ADAM33) gene polymorphism association with asthma in Egyptian children 61population found no association between T2 and Ig E level in
asthmatic patients, but a signiﬁcant association between T1
and high total Ig E (p0.04) and V4 with speciﬁc Ig E against
Blomia tropicalis (p0.03) a main source of sensitization in
tropical environments [12].
There was also a statistically signiﬁcant relation between
passive smoking as a precipitating factor in asthmatic patients
and ADAM33 V4 polymorphism (p= 0.001). This ﬁnding
could explain the structural changes in the airway associated
with exposure to passive smoking whether intrauterine or post-
natal. This is in agreement with another study done on an
adult population where V4 was signiﬁcantly associated with
COPD (chronic obstructive pulmonary disease) and lung func-
tion decline in long term smokers [28].
In the present study, the most prevalent precipitating fac-
tors associated with triggering asthma symptoms were upper
respiratory tract infections, exercise and exposure to tobacco
smoke in 68%, 60%, and 58.3% respectively. Respiratory tract
infections are the most common trigger for asthma symptoms
in all age groups but particularly in infants and young chil-
dren. There is substantial evidence that exposure to environ-
mental tobacco smoke in early childhood is a risk for
susceptibility and severity of asthma and related phenotypes
such as decreased lung function, airway hyperresponsiveness
(AHR) and wheezing in childhood [29].
Although there was no signiﬁcant relation between either
the absolute eosinophil count or Ig E level and the level of
asthma severity or the presence of atopic manifestations in pa-
tients, however a signiﬁcant relation between results of pul-
monary functions and the absolute eosinophil count, but not
the Ig E level, was observed. This ﬁnding was consistent with
that of 2 studies that reported no observed relation between to-
tal serum Ig E and decline in FEV1 [30,31] in allergic asthmat-
ics. Another study showed inverse association between
pulmonary (FEV1, FVC) functions and total serum Ig E in
middle aged and older men with history of smoking [32].
And in a study, asthmatic patients had higher total Ig E values
(p= 0.0003), higher speciﬁc Ig E values (0.02), higher preva-
lence of sensitization to house dust mite (0.002), and lower va-
lue of FEV1/FVC (p= 0.0005) [33].
It is suggested that these clinical and immunological differ-
ences reﬂect an intrinsic genetic diversity in the immunological
mechanism of allergic response.
Comparison of our results with other studies indicates that
no single SNP was universally associated with the asthma phe-
notype. The genetic basis of asthma may differ between differ-
ent ethnic groups; it is possible that a particular subset of SNPs
may be a risk factor for asthma in a speciﬁc population, and
that a different subset may increase the risk in another popu-
lation. The negligible association observed in this study may
suggest that either a small sample size may have affected the
results; or the presence of other alleles of interest not been cov-
ered by this study. Also gene haplotypes may have stronger im-
pact on phenotypes of this disease rather than single SNPs.
Also the role of this gene in the pathophysiology of asthma
remains controversial.6. Conclusion
Asthma is a complex phenotype that likely results from inter-
actions between multiple genetic and environmental factors.Because the etiology of asthma is likely to be multifactorial,
it is not surprising that multiple genes have been reported to
be associated with asthma but none with so great a statistical
signiﬁcance as the ADAM33 gene. In the present study, we
could not demonstrate a signiﬁcant association between
ADAM33 T1, T2 and V4 polymorphisms and the diagnosis
of asthma. A higher frequency in the T1 (AA) genotype among
controls and (AG) among patients with the overall higher fre-
quency of A allele in controls and G allele in the patients has
been observed but without statistical signiﬁcance. No signiﬁ-
cant correlation between ADAM33 T1, T2 and V4 and any
demographic, clinical, or laboratory parameters has been
established, except for a signiﬁcant association between T1
and total Ig E level, V4 and passive smoking as a precipitating
factor, and borderline signiﬁcance with absolute eosinophil
count. Finally there was no signiﬁcant relation between the le-
vel of asthma severity or the presence of atopic manifestations
and either the absolute eosinophilic count or Ig E, but a signif-
icant association between the results of pulmonary functions
ands the absolute eosinophilic count, but not with Ig E level.References
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